TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30616462
Drug: Gastric H.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric H. pylori treatment alone
Study: 29489568
Drug: Early Physical
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early Physical Therapy (PT) for 3 weeks
Study: 22311995
Drug: Child-targeted intervention
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child-targeted intervention (massage and humor therapy)
Study: 17657948
Drug: Antihomotoxic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihomotoxic therapy
Study: 11914565
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml of crystalloid solution for preloading (Group A)
Study: 11914565
Drug: 15 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml/kg of crystalloid solution for preloading (Group B)
Study: 10023505
Drug: Fluoxetine (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (n = 10)
Study: 2260153
Drug: Nimodipine 120
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine 120 mg orally
Study: 31191790
Drug: Intermittent pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent pneumatic compression along with conventional treatment
Study: 31191790
Drug: Cold-pack treatment
Normalized name: COLD PACK,INSTANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-pack treatment along with conventional treatment
Study: 29257757
Drug: Formulation containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation containing buradae sandal safaid, safoofe maghze tukhme bakayin, safoofe khaste tamar hindi and safoofe shakkar safaid, 10 g B.D for 21 days
Study: 29257757
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of azithromycin, fluconazole and secnidazole, single dose
Study: 11915783
Drug: HIGH carbohydrate
Normalized name: High carbohydrate food
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIGH carbohydrate diet (greater than 70% of daily energy intake from CHO)
Study: 11915783
Drug: LOW carbohydrate
Normalized name: Low carbohydrate beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOW carbohydrate diet (less than 10% of daily energy intake from CHO)
Study: 2577393
Drug: Clindamycin (q.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (q.i.d. 300 mg)
Study: 2577393
Drug: Cephradine (q.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephradine (q.i.d. 250 mg)
Study: 22372918
Drug: Standard community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard community care (CC) including nurse home visitation
Study: 21825006
Drug: Olaparib in
Normalized name: Product containing olaparib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib in combination with fractionated radiotherapy
Study: 21825006
Drug: Olaparib alone
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib alone or in combination with fractionated radiotherapy
Study: 15544709
Drug: Topical vapocoolant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vapocoolant Fluori‐Methane (FM)
Study: 11764063
Drug: Interapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interapy treatment (experimental condition)
Study: 9338731
Drug: Terazosin (alpha1-adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (alpha1-adrenergic antagonist)
Study: 8239013
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 50 micrograms.kg‐1.min‐1
Study: 8239013
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 75 micrograms.kg‐1.min‐1
Study: 8239013
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 100 micrograms.kg‐1.min‐1
Study: 8239013
Drug: Initial bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial bolus of propofol (2 mg.kg‐1)
Study: 8239013
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (all doses)
Study: 3300953
Drug: Chemotherapy (six
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (six cycles of vincristine, doxorubicin, and cyclophosphamide)
Study: 3300953
Drug: Levamisole immunotherapy
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole immunotherapy (150 mg/day, on 2 consecutive days weekly)
Study: 26120010
Drug: Ethinyl estradiol/norgestimate
Normalized name: ETHINYL ESTRADIOL/NORGESTIMATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinyl estradiol/norgestimate (0.035/0.25 mg once daily)
Study: 20106825
Drug: Low-dose cyclosporine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporine (CsA)
Study: 20106825
Drug: Low-dose tacrolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tacrolimus (Tac)
Study: 20106825
Drug: Low-dose sirolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sirolimus (SRL)
Study: 20106825
Drug: Standard-dose cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose cyclosporine (CsA)
Study: 20106825
Drug: Standard-dose cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose cyclosporine without induction
Study: 17651705
Drug: High-dose olanzapine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose olanzapine (up to 30 mg/day)
Study: 17651705
Drug: Clozapine and
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine and High-dose olanzapine
Study: 15653968
Drug: High-flow transtracheal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow transtracheal insufflation of oxygen-enriched air at 15 L/min (fraction of inspired oxygen, 0.37)
Study: 15653968
Drug: Low-flow transtracheal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flow transtracheal insufflation of oxygen at 1.5 L/min
Study: 10841003
Drug: Prediction rule
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction rule based on sulfonylurea Rx, insulin Rx, duration of diabetes, and fasting glucose levels
Study: 9347199
Drug: Ethanol infusion
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol infusion alone
Study: 29851090
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (LLLT) in addition to conventional therapy (compression garments, massage therapy, exercise) for 6 weeks; treatment details: wavelength 980/810 nm (80:20 ratio), output power 500 mW, beam spot size 5 cm2, irradiance 100 mW/cm2, treatment time per area 1 minute, total dosage delivered 300 J.
Study: 29851090
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy alone (compression garments, massage therapy, exercise).
Study: 9188997
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg midazolam
Study: 9188997
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg midazolam
Study: 20863007
Drug: Test FDC
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test FDC (rabeprazole 20 mg and diclofenac sodium 100 mg)
Study: 20863007
Drug: Reference FDC
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference FDC (rabeprazole 20 mg and diclofenac sodium 100 mg)
Study: 15745762
Drug: Brimonidine tartrate
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine tartrate 0.2% (twice daily)
Study: 15745762
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate 0.5% (twice daily)
Study: 11054909
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and thienopyridines (specific dosages and duration not mentioned)
Study: 11054909
Drug: Newer and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer and more potent antiplatelet agents (specific agents not mentioned)
Study: 11054909
Drug: Optimization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimization of antiplatelet therapy with aspirin and thienopyridines
Study: 8842505
Drug: Nanterinone 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanterinone 2 mg
Study: 30497837
Drug: 6 µg
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 µg hemagglutinin per strain (FluArt, Hungary)
Study: 30497837
Drug: 15 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 µg hemagglutinin per strain (currently licensed vaccine)
Study: 15023611
Drug: 500 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/d vitamin C
Study: 15023611
Drug: 1000 mg/d
Normalized name: RibaTab 1000 MG/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/d grape-seed polyphenols
Study: 1491345
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of moxisylyte (two formulations)
Study: 3085257
Drug: Nebulised sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised sodium cromoglycate (single high dose)
Study: 30234925
Drug: short‐infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: short‐infusion
Study: 26470783
Drug: Exenatide (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (7.5 μg)
Study: 23383459
Drug: Acupuncture group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture group (scalp acupoint Dingnie Qianxiexian (MS 6) and body acupoints Neiguan (PC 6), Jianyu (LI 15), Sanyinjiao (SP 6), treated once daily for 20 days)
Study: 23383459
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine neurological therapies only)
Study: 20190281
Drug: VIA-2291 (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIA-2291 (25, 50, or 100 mg daily for 12 weeks)
Study: 10822428
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg L-dopa every 24 hours
Study: 10822428
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg L-dopa every 8 hours
Study: 10822428
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg L-dopa every 8 hours
Study: 10822428
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg L-dopa every 24 hours (3 months prolonged treatment)
Study: 10822428
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg L-dopa every 8 hours (3 months prolonged treatment)
Study: 24139977
Drug: Adapted cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted cognitive behaviour therapy (CBT-HA group)
Study: 24139977
Drug: Adapted cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted cognitive behaviour therapy (CBT-HA group) and Standard care
Study: 23759035
Drug: Guided online
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided online sleep training based on Cognitive Behavioral Therapy for insomnia.
Study: 17127828
Drug: Lamivudine at
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine at 100 mg/daily orally for 52 weeks
Study: 17127828
Drug: Lamivudine at
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine at 100 mg/die plus alpha-interferon at 6 MU subcutaneously three times weekly for 52 weeks
Study: 17127828
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (lamivudine plus alpha-interferon) for 40 weeks after pre-treatment with lamivudine for 12 weeks
Study: 11908357
Drug: Colgate Winterfresh
Normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colgate Winterfresh Gel (0.243% sodium fluoride in a silica base)
Study: 8999672
Drug: Russian hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Russian hepatitis B Combiotech vaccine (20 mg)
Study: 8999672
Drug: Recombivax‐HB vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombivax‐HB vaccine (10 mg)
Study: 1443845
Drug: Oxymetazoline hydrochloride
Normalized name: Oxymetazoline Hydrochloride
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxymetazoline hydrochloride (two sprays, 15 minutes before therapy)
Study: 1443845
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water (control group, two sprays, 15 minutes before therapy)
Study: 27935660
Drug: 0.12% CHX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% CHX mouthrinses (Group II) used twice a week for 4 months
Study: 25971288
Drug: Lower-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose edoxaban (LDE)
Study: 25971288
Drug: Higher-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose edoxaban (HDE)
Study: 16689041
Drug: Pill counts
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pill counts for psychotropic medications
Study: 16689041
Drug: Medication Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Management Administration Assessment (MMAA) role-play
Study: 15160510
Drug: Meropenem plus
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem plus amikacin (20 mg/kg every 8 h plus 15 mg/kg/d in 2 divided doses)
Study: 15160510
Drug: Piperacillin-tazobactam plus
Normalized name: piperacillin / tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam plus netilmicin (100 mg/4 mg/kg every 8 h plus 7 mg/kg every 24 h)
Study: 9001768
Drug: Loteprednol etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loteprednol etabonate 0.5% ophthalmic suspension (LE), q.i.d. for 6 weeks
Study: 8105785
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray (one week's treatment)
Study: 8105785
Drug: Budesonide (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (two weeks' treatment)
Study: 27566742
Drug: Deflazacort 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflazacort 0.9 mg/kg/d
Study: 27566742
Drug: Deflazacort 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflazacort 1.2 mg/kg/d
Study: 23925646
Drug: Intraperitoneal 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal 0.25% bupivacaine (100 mg)
Study: 16870658
Drug: OrM3 0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: OrM3 0.5, 2, 3 or 4 mg orally once daily
Study: 16870658
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide 36 mug by inhalation four times daily
Study: 8851905
Drug: Glucose (18.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (18.5% w/v solution)
Study: 8851905
Drug: Maize syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maize syrup solids (18.5% w/v solution)
Study: 8851905
Drug: Sucrose (18.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (18.5% w/v solution)
Study: 1632399
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (atenolol, dihydroergotamine, domperidone, cafedrine, elastic compression stockings)
Study: 6760390
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day of sobrerol for 14 days
Study: 6760390
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g glyceringuaiacol per day for 14 days
Study: 26813467
Drug: Prodigest® (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prodigest® (two capsules)
Study: 18508296
Drug: 24 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks of peginterferon‐alpha‐2a (180 microg/week) and ribavirin (1000‐1200 mg/day)
Study: 18508296
Drug: 48 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 48 weeks of peginterferon‐alpha‐2a (180 microg/week) and ribavirin (1000‐1200 mg/day)
Study: 9088894
Drug: 0.1 IE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 IE per kg body weight regular insulin (insulin induced hypoglycemia)
Study: 9088894
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml 0.9% sodium chloride (placebo)
Study: 9088894
Drug: 0.1 IE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 IE per kg body weight regular insulin plus glucose 10% (euglycemic hyperinsulinemic glucose clamp)
Study: 8192109
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (HDD) for 48 hours followed by intermediate-dose dexamethasone (IDD)
Study: 8192109
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (HDD) followed by no steroids with cranial radiotherapy
Study: 2855297
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (80 micrograms per treatment, intranasally, three times daily for 5 days)
Study: 11468426
Drug: d4T monotherapy
Normalized name: STAVUDINE (d4T)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d4T monotherapy for 8 weeks
Study: 31254201
Drug: Anthracycline-taxane-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline-taxane-based chemotherapy (51.1% of deaths occurred here)
Study: 29606226
Drug: S-Health smartphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-Health smartphone application with daily surveys on cravings, affects, triggers, responses to triggers, and social contexts.
Study: 29606226
Drug: Text messages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text messages from S-Health (e.g., HIV prevention and other educational materials).
Study: 27352175
Drug: C18 (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: C18 (18 mmol/l citrate solution)
Study: 27352175
Drug: C15 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: C15 (15 mmol/l citrate solution)
Study: 25001621
Drug: Sufentanil administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil administered intraoperatively and hydromorphone dosed postoperatively via target-controlled infusion (TCI) and patient-controlled analgesia (PCA) until 8 a.m. on the first postoperative day.
Study: 16158800
Drug: Debridement and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debridement and short-term usage of antimicrobial agents
Study: 12008938
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment with melagatran and ximelagatran or dalteparin (exact dosage not specified)
Study: 7568633
Drug: 0.4 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/kg EtOH
Study: 7568633
Drug: 0.6 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 g/kg EtOH
Study: 7568633
Drug: 0.8 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/kg EtOH
Study: 7568633
Drug: 1.0 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g/kg EtOH
Study: 2332569
Drug: Patch testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch testing with individual components of Propine
Study: 26246458
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg/day plus saxagliptin and metformin
Study: 26246458
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus saxagliptin and metformin
Study: 22935227
Drug: Varicella vaccine
Normalized name: Varicella vaccine
DrugBank: Varicella zoster vaccine (live/attenuated) (DB10318)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varicella vaccine in SLE patients (28 vaccinated)
Study: 11242149
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) 300 mg twice a day until labour, 600 mg at the beginning of labour, and 300 mg twice a day for 7 days post-partum (n = 23)
Study: 9586595
Drug: α‐adrenoceptor‐blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: α‐adrenoceptor‐blockers
Study: 9586595
Drug: 5‐α‐reductase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐α‐reductase inhibitors
Study: 9586595
Drug: More uroselective
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More uroselective α‐blockers
Study: 8147676
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs (specific drugs not mentioned)
Study: 8147676
Drug: Antihypertensive agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive agents (general)
Study: 23954313
Drug: CRF‐R1 antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRF‐R1 antagonist (GW876008) 20 mg or 200 mg
Study: 23954313
Drug: CRF‐R1 antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRF‐R1 antagonist (GW876008)
Study: 16542503
Drug: Oral clodronate
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clodronate (1,600 mg/day)